David Banach

An outbreak of an uncommon but not unheard-of illness is responsible for the deaths of at least three people who were on an international cruise ship. With the rest of the passengers and crew under observation in their home countries — including 18 Americans who went to a quarantine facility at the University of Nebraska — how worried do we need to be about hantavirus? Dr. David Banach, UConn Health infectious diseases physician and hospital epidemiologist, joins Dr. Anthony Alessi to explain what we’re dealing with, the public health implications, and how, unlike COVID, the medical community at least has some history with this virus. You can check out the podcast here: It doesn’t spread in the same way that COVID does, in the sense that there’s no established sort of asymptomatic or pre-symptomatic spread. — Dr. David Banach Dr. Banach explains that hantavirus is a rare but serious virus carried primarily by rodents and spread through exposure to rodent waste or contaminated environments. While most cases are isolated, clusters can occasionally occur. The discussion compares hantavirus to COVID-19, with Dr. Banach emphasizing that hantavirus spreads much less easily between humans and is therefore less likely to become a global pandemic. However, it can cause severe cardiopulmonary illness with a significantly higher mortality rate than COVID. There is currently no vaccine or specific antiviral treatment, meaning care is largely supportive for patients who become critically ill. Dr. Banach also addresses public anxiety and misinformation surrounding the outbreak, encouraging people to rely on trusted organizations such as the World Health Organization and the Centers for Disease Control and Prevention for accurate information. He notes that public health officials continue to closely monitor the situation, but at this stage the overall risk to the general public remains low. Interested in learning more? Simply click on Dr. Banach's icon to arrange a time to talk today.

Updated COVID-10 booster shots are rolling out across the United States, and these new bivalent formulations target the omicron BA.4 and BA.5 subvariants that have become the dominant circulating strains as well as the original form of the coronavirus. UConn Health's Dr. David Banach, an infectious diseases physician and hospital epidemiologist, spoke with UConn Today about the latest CDC vaccination guidelines and the significance of these updated boosters: What’s the difference between the monovalent and bivalent vaccines? The monovalent vaccines are the ones that have been available thus far. They contain a small piece of the mRNA component of the virus based on the original SARS-CoV-2 virus, sometimes termed as the “ancestral strain,” and are designed to generate an immune response to that original virus. We’ve seen with the omicron variant — and specifically with the BA.4 and BA.5 subvariants, which have appeared most recently — the virus has changed. The bivalent vaccine contains both the portion of the original ancestral virus mRNA as well as a portion of mRNA that is specific for the BA.4 and BA.5 subvariants that have been circulating most recently. The hope is, by more specifically targeting the most recent subvariants, the bivalent boosters will reduce the impact of COVID both on individuals who received them as well as the population. Conceptually it’s analogous to what has been done with the influenza vaccine. The technology’s a little different but it’s based on the same idea. It’s targeted against both the original strain and the BA.4 and BA.5 subvariants of omicron. What becomes of the monovalent vaccine? At this time the vaccination program will be a primary vaccine series with the original monovalent vaccine and booster doses using the bivalent vaccine. Why wouldn’t we just start people with the bivalent vaccine? Data showed the monovalent vaccine upfront provides that high level of protection. The bivalent vaccine has not been evaluated as a primary vaccine candidate, so we don’t have the data to support its use in that context. That’s how it was originally designed, to be a booster. Dr. Banach is a leading voice on the fight against the COVID-19 virus, and he's available to speak with the media. Click on his icon to arrange an interview today.

UConn Health’s Dr. David Banach explains how a fully vaccinated and boosted person could test positive, negative, and positive again for COVID-19 within a 10-day span If anything, I would say this situation actually reinforces the importance of vaccination. — Dr. David Banach President Biden is back in isolation, testing positive again for COVID-19 despite testing negative a week after his initial positive test July 21. It may be a puzzling sequence, but there is an explanation. “It’s unlikely this is anything other than the original infection resurfacing,” says Dr. David Banach, infectious diseases physician and hospital epidemiologist at UConn Health. Biden’s physician says the president had been taking the antiviral drug Paxlovid, which is a standard treatment for those with COVID-19 who are considered “high-risk,” including older patients. Biden is 79. “It’s not unheard of for people to take Paxlovid, clinically improve, be antigen-negative, then ‘rebound’ a few days later as antigen-positive,” Banach says. Antigens are substances that cause an immune response. Antigen tests are commonly used in at-home testing and can yield results in 15 minutes by detecting antigens specific to COVID-19. Antigen tests differ from PCR (polymerase chain reaction) tests, which look for genetic material that indicates a COVID-19 infection. Due to the nature of his position, the president tests routinely. PCR testing generally is not recommended within 90 days of infection because if frequently remains positive positive for a prolonged period of time, even after patients recover and are no longer contagious, so Biden was given antigen testing instead. All signs point to the Paxlovid suppressing the antigens to undetectable levels, resulting in temporary negative results, followed by the “rebound.” As of Tuesday Biden’s only symptoms were a “loose cough,” according to a memo from his physician, Dr. Kevin O’Connor, who reported, “He remains fever-free and in good spirits.” The White House says the president is fully vaccinated and up-to-date on all his recommended boosters. “While this is another example of someone getting infected despite being is fully vaccinated and boosted, it’s important to understand the vaccines protected the president from serious illness from infection,” Banach says. “If anything, I would say this situation actually reinforces the importance of vaccination, especially for older people, those who are immunocompromised, or those with other health problems that could make them more vulnerable to serious illness.” Looking to know more about this topic then let us help with your stories and coverage. Dr. David Banach is an expert on infectious diseases and epidemiology and is a leading expert on COVID-19 in America. To book an interview with Dr. Banach, click on his icon today.